These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
    Author: Baumgärtner M, Dickgiesser N, Müller S, Wundt W.
    Journal: Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361.
    Abstract:
    This study compares the minimum inhibitory concentrations of moxalactam and cefotaxime, two beta-lactam-antibiotics, with those of cefoxitin, cefuroxime, and cefazolin for 523 gram-positive and -negative strains. Moxalactam and cefotaxime inhibit nearly all clinically important Enterobacteriaceae at concentrations less than 0.05 microgram/ml. Cefoxitin, cefuroxime, and cefazolin suppress bacterial growth at about 5--10 times higher concentrations. All strains of Pseudomonas are normally resistant to those three established cephalosporins, but about 60% are susceptible to 32 micrograms/ml of cefotaxime and moxalactam, a concentration which falls below achievable serum levels however does not exhibit any therapeutical effect. Against Staphylococcus aureus cefazolin is the most effective of all antibiotics tested (MIC 0.125--1 microgram/ml), cefotaxime appears to be somewhat less active (MIC 2--4 micrograms/ml), and a minimum of 8 micrograms/ml of moxalactam is needed to prevent bacterial growth. Streptococcus faecalis seems to be resistant to 128 micrograms/ml of moxalactam whereas the effect of cefotaxime is quite different. After transfers of Enterobacteriaceae on media containing cefotaxime or moxalactam a striking decrease of susceptibility sometimes occurs.
    [Abstract] [Full Text] [Related] [New Search]